Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
All News
Article
Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.
Article
It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.
Article
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Article
Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.
Article
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br
Dr. John Cush
Tweet
Download this week’s podcast titled “Good as I Ever Was”. You can find us on SoundCloud and wherever you download your podcasts.
https://t.co/hVMf8X5Dx3 https://t.co/uUDCXzO2eU
Dr. John Cush
Tweet
Stroke risk is increased in arthritis (RR 1.36, 95% CI: 1.27–1.46); esp for RA (RR 1.38), AS (RR 1.49), PsA (1.33) & gout (1.40); but NOT osteoarthritis (RR=1.03). Apparently Inflammation drives this risk. https://t.co/Snb6OrtZJH
Dr. John Cush
Tweet
The FDA has informed Abbvie that their supplemental application for new indications (PsA and AS) for upadacitinib (Rinvoq) has been delayed; the FDA citing its ongoing review of tofacitinibs safety concerns stemming from the ORAL Surveillance RA study https://t.co/sSJyVtQNYu
Dr. John Cush
Tweet
Ten Things to Tell Patients About Diet and Rheumatic Disease: Dr. Eric Dein ( @ejdein1 )
https://t.co/q2Mc1gLZig https://t.co/iV5JO8m5Sv
Dr. John Cush
Tweet
Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi ( @MeralElRamahiMD )
reviews the panel from #EULAR2021.
https://t.co/pfYvfsCbiA
Dr. John Cush
Tweet
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. We've compiled some of the highlights.
https://t.co/NbBqPbbiUy https://t.co/FvsOhKtrHi
Dr. John Cush
Tweet
Why do female counterparts axSpA patients report worsening outcomes and worsening scores compared to their male counterparts?
https://t.co/6hXp4Lemyk https://t.co/RTuhATrtG9
Dr. John Cush
Tweet
Video: The PsA SpA Paradox of Choice
Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting.
https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
Dr. John Cush
Tweet
Video: Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi (@MeralElRamahiMD ) #EULAR2021
https://t.co/ocyR4ka8zO https://t.co/DxHjM0stKo
Dr. John Cush
Tweet
#EULAR2021 - Day 3 Report
https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo
Dr. John Cush
Tweet
Find all your AS/Spondyloarthritis coverage from #EULAR2021 in one spot.
https://t.co/owm8LQzHXr https://t.co/5YmDFOvolF
Meral K. El Ramahi, MD
Tweet
OP0140 at #EULAR2021:
➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz)
➡️1 in 10 received at least 3 bDMARDs
*⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis
@Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD
Tweet
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS
⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12
#EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Meral K. El Ramahi, MD
Tweet
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus
